649 results on '"Behrens, Frank"'
Search Results
2. Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE
3. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
4. Machine learning identifies right index finger tenderness as key signal of DAS28-CRP based psoriatic arthritis activity
5. Correction: Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
6. ALISTER – Application for lipid stability evaluation and research
7. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
8. Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units
9. Development of a Low-Cost Open Platform for Vital Signs Acquisition and Monitoring
10. PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis
11. Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study
12. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
13. Sensory testing and topical capsaicin can characterize patients with rheumatoid arthritis
14. An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study
15. Monitoring and Control of Electrical Machines Using IoT
16. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
17. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial
18. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials
19. Ixekizumab im Vergleich zu Fumarsäureestern und Methotrexat bei der Behandlung der Nagelpsoriasis bei Patienten mit mittelschwerer bis schwerer Psoriasis
20. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
21. Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
22. Development of a Low-Cost Open Platform for Vital Signs Acquisition and Monitoring
23. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study
24. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52
25. Behandlung der Psoriasis mit Secukinumab: Praxisrelevante Hinweise
26. IoT- Based Indicator for Industrial Accident Risks
27. Agile Project Implementation Methodology for Introducing New Technologies in Industry 4.0
28. Monitoring and Control of Electrical Machines Using IoT
29. Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate‐to‐severe psoriasis
30. A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action
31. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
32. Implementing an automated monitoring process in a digital, longitudinal observational cohort study
33. Charakterisierung von Patienten mit Psoriasisarthritis in der dermatologischen und rheumatologischen Versorgung: Analyse von zwei Registern
34. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
35. Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: analysis of two registries
36. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting
37. Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study
38. Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study
39. IoT- Based Indicator for Industrial Accident Risks
40. Individual therapeutic DAS28-dcrit responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies
41. Agile Project Implementation Methodology for Introducing New Technologies in Industry 4.0
42. Experimental Validation of Fuzzy Logic Based Routing Algorithm for Wireless Sensor Network Applied to Indoor Environments
43. Correction to: Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52
44. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
45. Solar-Energie für alle.
46. The role of antidrug antibodies in ustekinumab therapy and the impact of methotrexate.
47. Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.
48. Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting.
49. Machine learning identifies right index finger tenderness as key signal of DAS28- CRP based psoriatic arthritis activity
50. Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.